Washed Microbiota Transplantation for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe Second Hospital of Nanjing Medical University

About this trial

This is a prospective, randomized, multicenter study to evaluate WMT in improving nutritional status in malnourished patients who underwent nonphysiological reconstruction of the upper gastrointestinal tract. In this multicenter trial, sixty-two patients will be enrolled in forteen Chinese sites. Participants will be randomized at a ratio of 1:1 to receive three WMTs through either mid-gut tube or colonic TET. After WMT, each participant will receive free diet plus home enteral nutrition. Home enteral nutrition should last for 2 months at home, with blood, urine and stool samples taken and stored at baseline and 2 months after WMT.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients undergone nonphysiological reconstruction of the gastrointestinal tract (such as Billroth-II, Roux-en-Y, Child, Whipple reconstruction)

Aged over 18 years old;

Malnutrition is assessed by Nutritional Risk Screening 2002 score≥3 and Patient Generated Subjective Global Assessment (PG-SGA) score≥4;

Written informed consent;

Disqualifiers

Expected survival time < 3 months;

Still on anti-tumor therapy or it is expected during the visit;

Complicated with ascites or edema caused by malnutrition;

Known organic gastrointestinal disease (e.g., gastrointestinal infection, inflammatory bowel disease, or radiation enteritis);

Trial design

Design model

Parallel

Treatments tested in this trial

  • washed microbiota transplantation

    Other intervention

    Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.

Treatment groups

62 Participants
are divided into 2 treatment groups
Group A: midgutExperimental treatment 1 intervention
Group B: colonicExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Changes of weight and height

Weight and height will be combined to report BMI in kg/m\^2.

Time frame
baseline, 8 weeks post transplantation
2

Changes of the third lumbar vertebrae skeletal muscle mass and height

The third lumbar vertebrae skeletal muscle mass represents the sum of the cross-sectional areas of the skeletal muscles at the L3 level, including the psoas major, the erector spinae, the quadratus lumborum, the musculus transversus abdominis, the obliquus externus abdominis and the obliquus internus abdominis. Skeletal muscle mass and height will be combined to report the third lumbar vertebrae skeletal muscle mass index(L3 SMI) in cm\^2/m\^2.

Time frame
baseline, 8 weeks post transplantation
3

Changes of weight

Time frame
baseline, 8 weeks post transplantation

Secondary outcomes

1

Changes of Patient-Generated Subjective Global Assessment (PG-SGA)

Patient-Generated Subjective Global Assessment (PG-SGA) includes patient-generated historical components (Weight History, Food Intake, Symptoms and Activities and Function) and the professional part (Diagnosis, Age, Metabolic stress, and Physical Exam).

Time frame
baseline, 8 weeks post transplantation
2

Changes of the Gastrointestinal Symptom Rating Scale(GSRS)

GSRS is a 13-item test to make a comprehensive assessment of common gastrointestinal symptom and each item receives a value from 0 to 3, with higher value indicating worse gastrointestinal condition.

Time frame
baseline, 4 weeks, 8 weeks post transplantation
3

60-day readmission rate

The 60-day readmission is recorded and defined as nonelective readmission within 60 days after the treatment.

Time frame
From enrollment to the end of treatment at 8 weeks
4

The incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0

The severity of AE was graded as mild (grade 1), moderate (grade 2), severe/disabling (grade 3), life threatening (grade 4), and death (grade 5). All AE were divided in definitely, probably and possibly related to treatment. The treatment-related AE we focused on included microbiota-related AEs (e.g., infection, diarrhea, abdominal pain, etc.) and route of delivery related AEs (e.g., nausea, vomiting, etc.).

Time frame
From enrollment to the end of treatment at 8 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Second Hospital of Nanjing Medical University

Lead sponsor

The First Affiliated Hospital of Guangdong Pharmaceutical University

Collaborator

Nanjing Medical University

Collaborator

Wuxi No. 2 People's Hospital

Collaborator

Jiangxi University of Chinese Medicine Affiliated Hospital

Collaborator

Hubei Hospital of Traditional Chinese Medicine

Collaborator

The Affiliated Hospital Of Southwest Medical University

Collaborator

Tang-Du Hospital

Collaborator

Huzhou Central Hospital

Collaborator

West China Fourth Hospital

Collaborator

The Affiliated People's Hospital of Ningbo University

Collaborator

Guangzhou First People Hospital of Guangzhou Medical University

Collaborator

The First Affiliated Hospital of Anhui University of Chinese Medicine

Collaborator

Beijing Rectum Hospital

Collaborator

Dazhou Central Hospital

Collaborator

The Second Affiliated Hospital of Dalian Medical University

Collaborator

Second Affiliated Hospital of Guangzhou Medical University

Collaborator

PLA No. 901 Hospital of the Joint Support Force

Collaborator

YI'AN PEOPLE'S HOSPITAL

Collaborator

Hunan Aerospace Hospital

Collaborator

Jiamusi City Hospital of Traditional Chinese Medicine

Collaborator

The First People's Hospital of Kunshan

Collaborator

LanZhou University

Collaborator

Jingxing xian yiyuan

Collaborator

TAIHE country people's hospital

Collaborator

Tailai County People's Hospital

Collaborator

Armed Police Characteristic Medical Center

Collaborator

First Affiliated Hospital Xi'an Jiaotong University

Collaborator